标题
Pharmacotherapy of obesity: An update
作者
关键词
Obesity, Diabetes, Weight management, Glucagon receptor family, Individual variation
出版物
PHARMACOLOGICAL RESEARCH
Volume 169, Issue -, Pages 105649
出版商
Elsevier BV
发表日期
2021-05-05
DOI
10.1016/j.phrs.2021.105649
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Obesity Management in Women of Reproductive Age
- (2021) S. Michelle Ogunwole et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
- (2021) Young Jin Tak et al. Current Obesity Reports
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
- (2020) Juan Pablo Frias et al. DIABETES OBESITY & METABOLISM
- Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
- (2020) Thomas A. Wadden et al. Obesity
- Modern pharmacological treatment of obese patients
- (2020) Marcus May et al. Therapeutic Advances in Endocrinology and Metabolism
- Obesity, polycystic ovary syndrome and infertility: a new avenue for GLP-1 receptor agonists
- (2020) Hellas Cena et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
- (2020) Aaron S. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
- (2020) John Sharretts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
- (2020) Olof Eriksson et al. Scientific Reports
- Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
- (2020) Andrea Cignarella et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
- (2020) Karine Clément et al. Lancet Diabetes & Endocrinology
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
- (2020) Thinzar Min et al. Diabetes Therapy
- Obesity is associated with impaired responsiveness to once‐daily low‐dose aspirin and in vivo platelet activation
- (2019) Giovanna Petrucci et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
- (2019) Kentaro Kaneko et al. JOURNAL OF CLINICAL INVESTIGATION
- Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children
- (2019) Kathryn E. Kyler et al. PEDIATRIC DRUGS
- Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist
- (2019) Victoria E R Parker et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity
- (2019) Kong Y. Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study
- (2019) Elisé G. Kaboré et al. PLOS MEDICINE
- Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs
- (2019) Awadhesh Kumar Singh et al. Expert Review of Clinical Pharmacology
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes
- (2018) Megan E Capozzi et al. ENDOCRINE REVIEWS
- Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
- (2018) Peter M Rothwell et al. LANCET
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- (2018) Erin A. Bohula et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis
- (2018) F.-F. Wang et al. Obesity Reviews
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Pharmacotherapy of obesity: Available medications and drugs under investigation
- (2018) Eleni Pilitsi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages
- (2017) Inigo Ruiz de Azua et al. JOURNAL OF CLINICAL INVESTIGATION
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Current pharmacotherapy for obesity
- (2017) Gitanjali Srivastava et al. Nature Reviews Endocrinology
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Lorcaserin improves glycemic control via a melanocortin neurocircuit
- (2017) Luke K. Burke et al. Molecular Metabolism
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Management of obesity
- (2016) George A Bray et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Naltrexone ER/Bupropion ER: A Review in Obesity Management
- (2015) Sarah L. Greig et al. DRUGS
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Echocardiographic Assessment of Cardiac Valvular Regurgitation With Lorcaserin From Analysis of 3 Phase 3 Clinical Trials
- (2013) Neil J. Weissman et al. Circulation-Cardiovascular Imaging
- Reasons for and Time to Discontinuation of Rimonabant Therapy
- (2013) Marjolein J. C. Willemen et al. DRUG SAFETY
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Under-reporting of adverse effects of tesofensine
- (2013) Arne Astrup et al. LANCET
- Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats
- (2013) Bo Hjorth Bentzen et al. Obesity
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Loss of Control of HIV Viremia Associated with the Fat Malabsorption Drug Orlistat
- (2012) Stephen J. Kent AIDS RESEARCH AND HUMAN RETROVIRUSES
- Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria
- (2012) B. O. Yildiz et al. HUMAN REPRODUCTION
- Anti-Obesity Drugs: A Review about Their Effects and Safety
- (2012) Jun Goo Kang et al. Diabetes & Metabolism Journal
- Implications of Obesity for Drug Therapy: Limitations and Challenges
- (2011) R Jain et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
- (2010) A Sjödin et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Effects of Maternal Surgical Weight Loss in Mothers on Intergenerational Transmission of Obesity
- (2009) J. Smith et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice
- (2009) K. Ganesh Kumar et al. PEPTIDES
- Cannabinoid Type 1 Receptor Blockade Promotes Mitochondrial Biogenesis Through Endothelial Nitric Oxide Synthase Expression in White Adipocytes
- (2008) L. Tedesco et al. DIABETES
- Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization
- (2008) W. J. Thomsen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started